Literature DB >> 8118026

Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha.

F Rosselli1, J Sanceau, E Gluckman, J Wietzerbin, E Moustacchi.   

Abstract

We have previously shown an unbalanced cytokine production in Fanconi anemia (FA) cells, ie, an underproduction of interleukin 6 (IL-6) during growth. Among a number of cytokines analyzed, the only other anomalies detected concern tumor necrosis factor alpha (TNF alpha). In comparison to normal cells, this cytokine is overproduced by FA lymphoblasts from the four genetic complementation groups. Indeed, up to an eight-fold increase in TNF alpha is observed in the growth medium of FA cells. Moreover, addition of anti-TNF alpha antibodies partially corrects the FA hypersensitivity to treatment by mitomycin C (MMC). Treatment of FA cells with IL-6, which partially restored an almost normal sensitivity to MMC of FA cells also reduces the TNF alpha overproduction in FA lymphoblasts. No anomalies at the molecular level (Southern and Northern blot analyses) are detected for the TNF alpha gene and its mRNA. We have investigated the in vivo situation by assaying TNF alpha levels in the serum from FA homozygotes and obligate heterozygotes. In contrast to normal healthy donors or to aplastic anemia patients in whom serum TNF alpha is present only in trace amounts, all 36 FA patients and 21 FA parents monitored show a significantly (P < .001) higher level of serum TNF alpha activity. Consequently, abnormal TNF alpha production seems to be associated with the FA genetic background.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8118026

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

Review 1.  Fanconi anaemia.

Authors:  M D Tischkowitz; S V Hodgson
Journal:  J Med Genet       Date:  2003-01       Impact factor: 6.318

2.  Impaired function of Fanconi anemia type C-deficient macrophages.

Authors:  Ying Liu; Kimberly Ballman; Deqiang Li; Shehnaz Khan; Ethel Derr-Yellin; Weinian Shou; Laura S Haneline
Journal:  J Leukoc Biol       Date:  2011-11-21       Impact factor: 4.962

Review 3.  Mouse models of Fanconi anemia.

Authors:  Kalindi Parmar; Alan D'Andrea; Laura J Niedernhofer
Journal:  Mutat Res       Date:  2009-04-10       Impact factor: 2.433

4.  Cytokine production by bone marrow mononuclear cells in inherited bone marrow failure syndromes.

Authors:  Ken Matsui; Neelam Giri; Blanche P Alter; Ligia A Pinto
Journal:  Br J Haematol       Date:  2013-07-25       Impact factor: 6.998

Review 5.  Oxidative stress-associated protein tyrosine kinases and phosphatases in Fanconi anemia.

Authors:  Jie Li; Qishen Pang
Journal:  Antioxid Redox Signal       Date:  2014-03-11       Impact factor: 8.401

Review 6.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

7.  Fanconi anemia proteins and endogenous stresses.

Authors:  Qishen Pang; Paul R Andreassen
Journal:  Mutat Res       Date:  2009-07-31       Impact factor: 2.433

8.  Microphthalmia transcription factor expression contributes to bone marrow failure in Fanconi anemia.

Authors:  Alessia Oppezzo; Julie Bourseguin; Emilie Renaud; Patrycja Pawlikowska; Filippo Rosselli
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

9.  Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha.

Authors:  J P Maciejewski; C Selleri; T Sato; H J Cho; L K Keefer; C F Nathan; N S Young
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

10.  Defective homing is associated with altered Cdc42 activity in cells from patients with Fanconi anemia group A.

Authors:  Xiaoling Zhang; Xun Shang; Fukun Guo; Kim Murphy; Michelle Kirby; Patrick Kelly; Lilith Reeves; Franklin O Smith; David A Williams; Yi Zheng; Qishen Pang
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.